Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities

August 25, 2026

Cambrex, a global contract development and manufacturing organization (CDMO), has announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA). The completion of these inspections allows the High Point facility to manufacture approved active pharmaceutical ingredients (APIs) for the United States, Japan, and Australia, marking it as the newest commercial manufacturing site within the Cambrex global network.

PAIs are conducted by regulatory agencies to evaluate a facility's quality systems, manufacturing processes, data integrity, and operational controls before commercial products can be approved for manufacture at the site.

This milestone follows Cambrex's $38 million expansion of the High Point facility, which was completed in 2023. The expansion added analytical and chemical development laboratories, clinical manufacturing suites, and commercial manufacturing operations equipped with reactors up to 2,000 liters. The site is specifically designed to support lower-volume commercial products, including orphan drugs, precision medicines, and other specialized therapies targeting smaller patient populations.

"Successfully completing these inspections demonstrates the strength of our quality systems and the dedication of the High Point team," said Thomas Loewald, Chief Executive Officer of Cambrex. "As more therapies are developed for targeted patient populations, the industry increasingly requires commercial manufacturing capacity at smaller scales. High Point was purpose-built to meet that need, providing customers with an efficient and flexible path from development to long-term commercial supply."

The High Point facility enhances Cambrex's global development and manufacturing network by offering customers a seamless path from process development and clinical manufacturing to commercial production. The addition of commercial manufacturing capabilities in North Carolina further strengthens the company's capacity to support customer programs throughout the product lifecycle.

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing services across the entire drug lifecycle, along with comprehensive analytical services. With over 45 years of experience and a team of 2,000 experts servicing clients worldwide from North America and Europe, Cambrex offers a variety of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex synthetics, and highly potent APIs.

Share
Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.